SCHEMBL12401872

SCHEMBL12401872

N=C(N)CCc1ccc(CCCCCc2ccc(CCC(=N)N)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.43
HIF1A Q16665 2/20 0.43
NOS1 P29475 2/20 0.43
NPC1 O15118 1/20 0.43
CYP2D6 P10635 1/20 0.43
RAB9A P51151 1/20 0.43
SPHK1 Q9NYA1 4/20 0.42
ESR1 P03372 2/20 0.42
ADRA2A P08913 2/20 0.42
ADORA3 P0DMS8 2/20 0.42
TACR2 P21452 2/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
SPHK2 Q9NRA0 2/20 0.42
ACHE P22303 2/20 0.42
BLM P54132 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12401897 0.93 NOS1 (0.45) CYP3A4HIF1ANOS1NPC1CYP2D6
SCHEMBL12376924 0.91 NOS1 (0.43) CYP3A4HIF1ANOS1NPC1CYP2D6
SCHEMBL8780954 0.91 NOS1 (0.50) CYP3A4HIF1ANOS1NPC1CYP2D6
SCHEMBL13819007 0.86 NOS1 (0.46) CYP3A4HIF1ANOS1NPC1CYP2D6
SCHEMBL16934391 0.82 SPHK2 (0.61) CYP3A4HIF1ASPHK1ESR1ADRA2A
SCHEMBL6198752 0.81 MAPT (0.60) NOS1SLC6A3ACHEMAPTRXFP1
SCHEMBL1542295 0.81 PRMT1 (0.58) CYP2D6ADRA2ASLC6A2SLC6A4SLC6A3
SCHEMBL1542151 0.81 PRMT1 (0.58) CYP2D6ADRA2ASLC6A2SLC6A4SLC6A3
SCHEMBL1542209 0.81 PRMT1 (0.58) CYP2D6ADRA2ASLC6A2SLC6A4SLC6A3
SCHEMBL1542105 0.81 PRMT1 (0.58) CYP2D6ADRA2ASLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703825-B2 Compounds, use thereof as medicaments, and method of preparation thereof UNIVERSITE DE LORRAINE (FR) 2014-04-22 US disclosed
US-20110184070-A1 NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF UNIVERSITE HENRI POINCARE NANCY 1 (FR) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110184070-A1 NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF CYP11B2, NPM1, B2M CYP3A4 569/4885HIF1A 875/4885NOS1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.